Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss

FASEB Journal

Volumn 29, Issue 3, 2015, Pages 1092-1101

  Guan, Hanfeng ^a   Zhao, Libo ^a   Cao, Huijuan ^b   Chen, Anmin ^a   Xiao, Jun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

NF B; Osteoclast; Osteoporosis; RANK

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; EPOXYICOSATRIENOIC ACID; GELATINASE B; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; ACID PHOSPHATASE; DIHOMO GAMMA LINOLENIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOENZYME; MESSENGER RNA; TARTRATE-RESISTANT ACID PHOSPHATASE; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; ETIOLOGY; GENETICS; HUMAN; METABOLISM; OSTEOCLAST; PATHOLOGY; PREVENTION AND CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

8,11,14-EICOSATRIENOIC ACID; ACID PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; BONE RESORPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; ISOENZYMES; MICE, INBRED C57BL; NF-KAPPA B; OSTEOCLASTS; OVARIECTOMY; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; VASODILATOR AGENTS;

EID: 84937421430     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-262055     Document Type: Article

References (52)

1. Kikuta, J., and Ishii, M. (2013) Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 52, 226-234
2. Nakashima, T., Hayashi, M., Fukunaga, T., Kurata, K., Oh-Hora, M., Feng, J. Q., Bonewald, L. F., Kodama, T., Wutz, A., Wagner, E. F., Penninger, J. M., and Takayanagi, H. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234
3. Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., and O'Brien, C. A. (2011) Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235-1241
4. Li, C., Yang, Z., Li, Z., Ma, Y., Zhang, L., Zheng, C., Qiu, W., Wu, X., Wang, X., Li, H., Wang, P., Luo, J., and Liu, M. (2011) Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. J. Bone Miner. Res. 26, 644-656
5. Lee, S. E., Chung, W. J., Kwak, H. B., Chung, C. H., Kwack, K. B., Lee, Z. H., and Kim, H. H. (2001) Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J. Biol. Chem. 276, 49343-49349
6. Lee, Z. H., and Kim, H. H. (2003) Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305, 211-214
7. Kwak, H. B., Sun, H. M., Ha, H., Lee, J. H., Kim, H. N., and Lee, Z. H. (2008) AG490, a Jak2-specific inhibitor, induces osteoclast survival by activating the Akt and ERK signaling pathways. Mol. Cells 26, 436-442
8. Lee, N. K., Choi, Y. G., Baik, J. Y., Han, S. Y., Jeong, D. W., Bae, Y. S., Kim, N., and Lee, S. Y. (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106, 852-859
9. Kim, H. J., Chang, E. J., Kim, H. M., Lee, S. B., Kim, H. D., Su Kim, G., and Kim, H. H. (2006) Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Free Radic. Biol. Med. 40, 1483-1493
10. Sasaki, H., Yamamoto, H., Tominaga, K., Masuda, K., Kawai, T., Teshima-Kondo, S., and Rokutan, K. (2009) NADPH oxidase-derived reactive oxygen species are essential for differentiation of a mouse macrophage cell line (RAW264.7) into osteoclasts. J. Med. Invest. 56, 33-41
11. Teitelbaum, S. L., and Ross, F. P. (2003) Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649
12. Spector, A. A. (2009) Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res. 50(Suppl), S52-S56
13. Xu, X., Zhang, X. A., and Wang, D. W. (2011) The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv. Drug Deliv. Rev. 63, 597-609
14. Node, K., Huo, Y., Ruan, X., Yang, B., Spiecker, M., Ley, K., Zeldin, D. C., and Liao, J. K. (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285, 1276-1279
15. Schmelzer, K. R., Kubala, L., Newman, J. W., Kim, I. H., Eiserich, J. P., and Hammock, B. D. (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. USA 102, 9772-9777
16. Smith, K. R., Pinkerton, K. E., Watanabe, T., Pedersen, T. L., Ma, S. J., and Hammock, B. D. (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. Proc. Natl. Acad. Sci. USA 102, 2186-2191
17. Seubert, J. M., Zeldin, D. C., Nithipatikom, K., and Gross, G. J. (2007) Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 82, 50-59
18. Liu, Y., Zhang, Y., Schmelzer, K., Lee, T. S., Fang, X., Zhu, Y., Spector, A. A., Gill, S., Morisseau, C., Hammock, B. D., and Shyy, J. Y. (2005) The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA 102, 16747-16752
19. Fleming, I. (2001) Cytochrome p450 and vascular homeostasis. Circ. Res. 89, 753-762
20. Imig, J. D. (2010) Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol. 56, 329-335
21. Dhanasekaran, A., Al-Saghir, R., Lopez, B., Zhu, D., Gutterman, D. D., Jacobs, E. R., and Medhora, M. (2006) Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature. Am. J. Physiol. Heart Circ. Physiol. 291, H517-H531
22. Yang, S., Lin, L., Chen, J. X., Lee, C. R., Seubert, J. M., Wang, Y., Wang, H., Chao, Z. R., Tao, D. D., Gong, J. P., Lu, Z. Y., Wang, D. W., and Zeldin, D. C. (2007) Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 293, H142-H151
23. Chen, J. K., Falck, J. R., Reddy, K. M., Capdevila, J., and Harris, R. C. (1998) Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J. Biol. Chem. 273, 29254-29261
24. Chen, J. K., Capdevila, J., and Harris, R. C. (2002) Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc. Natl. Acad. Sci. USA 99, 6029-6034
25. Panigrahy, D., Kalish, B. T., Huang, S., Bielenberg, D. R., Le, H. D., Yang, J., Edin, M. L., Lee, C. R., Benny, O., Mudge, D. K., Butterfield, C. E., Mammoto, A., Mammoto, T., Inceoglu, B., Jenkins, R. L., Simpson, M. A., Akino, T., Lih, F. B., Tomer, K. B., Ingber, D. E., Hammock, B. D., Falck, J. R., Manthati, V. L., Kaipainen, A., D'Amore, P. A., Puder, M., Zeldin, D. C., and Kieran, M. W. (2013) Epoxyeicosanoids promote organ and tissue regeneration. Proc. Natl. Acad. Sci. USA 110, 13528-13533
26. Panigrahy, D., Edin, M. L., Lee, C. R., Huang, S., Bielenberg, D.R., Butterfield, C. E., Barnés, C. M., Mammoto, A., Mammoto, T., Luria, A., Benny, O., Chaponis, D. M., Dudley, A. C., Greene, E. R., Vergilio, J. A., Pietramaggiori, G., Scherer-Pietramaggiori, S. S., Short, S. M., Seth, M., Lih, F. B., Tomer, K. B., Yang, J., Schwendener, R. A., Hammock, B. D., Falck, J. R., Manthati, V. L., Ingber, D. E., Kaipainen, A., D'Amore, P. A., Kieran, M. W., and Zeldin, D. C. (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J. Clin. Invest. 122, 178-191
27. Koerner, I. P., Zhang, W., Cheng, J., Parker, S., Hurn, P. D., and Alkayed, N. J. (2008) Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front. Biosci. 13, 2833-2841
28. Mundy, G. R. (2007) Osteoporosis and inflammation. Nutr. Rev. 65, S147-S151
29. Yu, X., Huang, Y., Collin-Osdoby, P., and Osdoby, P. (2004) CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J. Bone Miner. Res. 19, 2065-2077
30. Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J., and Müller, R. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468-1486
31. Asagiri, M., and Takayanagi, H. (2007) The molecular understanding of osteoclast differentiation. Bone 40, 251-264
32. Guan, H., Xie, L., Leithäuser, F., Flossbach, L., Möller, P., Wirth, T., and Ushmorov, A. (2010) KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood 116, 1469-1478
33. Guan, H., Xie, L., Klapproth, K., Weitzer, C. D., Wirth, T., and Ushmorov, A. (2013) Decitabine represses translocated MYC oncogene in Burkitt lymphoma. J. Pathol. 229, 775-783
34. Dhanasekaran, A., Gruenloh, S. K., Buonaccorsi, J. N., Zhang, R., Gross, G. J., Falck, J. R., Patel, P. K., Jacobs, E. R., and Medhora, M. (2008) Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294, H724-H735
35. Takayanagi, H. (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat. Rev. Immunol. 7, 292-304
36. Takayanagi, H. (2007) The role of NFAT in osteoclast formation. Ann. N. Y. Acad. Sci. 1116, 227-237
37. Manolagas, S. C., O'Brien, C. A., and Almeida, M. (2013) The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699-712
38. Edwards, J. R., and Mundy, G. R. (2011) Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 7, 235-243
39. Cenci, S., Weitzmann, M. N., Roggia, C., Namba, N., Novack, D., Woodring, J., and Pacifici, R. (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 106, 1229-1237
40. Roggia, C., Gao, Y., Cenci, S., Weitzmann, M. N., Toraldo, G., Isaia, G., and Pacifici, R. (2001) Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98, 13960-13965
41. Gao, Y., Feng, J., Ma, K., Zhou, Z., Zhu, Y., Xu, Q., and Wang, X. (2012) 8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in mice. PLoS ONE 7, e40258
42. Jimi, E., Aoki, K., Saito, H., D'Acquisto, F., May, M. J., Nakamura, I., Sudo, T., Kojima, T., Okamoto, F., Fukushima, H., Okabe, K., Ohya, K., and Ghosh, S. (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10, 617-624
43. Armstrong, A. P., Tometsko, M. E., Glaccum, M., Sutherland, C. L., Cosman, D., and Dougall, W. C. (2002) A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J. Biol. Chem. 277, 44347-44356
44. Frömel, T., Jungblut, B., Hu, J., Trouvain, C., Barbosa-Sicard, E., Popp, R., Liebner, S., Dimmeler, S., Hammock, B. D., and Fleming, I. (2012) Soluble epoxide hydrolase regulates hematopoietic progenitor cell function via generation of fatty acid diols. Proc. Natl. Acad. Sci. USA 109, 9995-10000
45. Vanella, L., Kim, D. H., Sodhi, K., Barbagallo, I., Burgess, A. P., Falck, J. R., Schwartzman, M. L., and Abraham, N. G. (2011) Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes. Prostaglandins Other Lipid Mediat. 96, 54-62
46. Wang, D., and Dubois, R. N. (2012) Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J. Clin. Invest. 122, 19-22
47. Yang, W., Holmes, B. B., Gopal, V. R., Kishore, R. V., Sangras, B., Yi, X. Y., Falck, J. R., and Campbell, W. B. (2007) Characterization of 14,15-epoxyeicosatrienoyl-sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J. Pharmacol. Exp. Ther. 321, 1023-1031
48. Imig, J. D., Zhao, X., Capdevila, J. H., Morisseau, C., and Hammock, B. D. (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39, 690-694
49. Lee, C. R., Imig, J. D., Edin, M. L., Foley, J., DeGraff, L. M., Bradbury, J. A., Graves, J. P., Lih, F. B., Clark, J., Myers, P., Perrow, A. L., Lepp, A. N., Kannon, M. A., Ronnekleiv, O. K., Alkayed, N. J., Falck, J. R., Tomer, K. B., and Zeldin, D. C. (2010) Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24, 3770-3781
50. Gross, G. J., Gauthier, K. M., Moore, J., Falck, J. R., Hammock, B. D., Campbell, W. B., and Nithipatikom, K. (2008) Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. Heart Circ. Physiol. 294, H2838-H2844
51. Imig, J. D., Simpkins, A. N., Renic, M., and Harder, D. R. (2011) Cytochrome P450 eicosanoids and cerebral vascular function. Expert Rev. Mol. Med. 13, e7
52. Imig, J. D., and Hammock, B. D. (2009) Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8, 794-805